Skip to content 
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska. more
| Time Frame | KLTO | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 2.16% | 0.72% | -1.31% |
| 1-Month Return | -24.12% | 1.27% | 0.78% |
| 3-Month Return | -50% | 3.13% | 3.46% |
| 6-Month Return | -69.97% | 15.81% | 6.19% |
| 1-Year Return | -41% | 8.89% | 11.68% |
| 3-Year Return | -97.69% | 20.79% | 71.21% |
| 5-Year Return | -97.61% | 35.89% | 74.81% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 913.15 | 1.11M | 574.37K | 631.32K | 5.54M | [{"date":"2020-12-31","value":0.02,"profit":true},{"date":"2021-12-31","value":20.02,"profit":true},{"date":"2022-12-31","value":10.37,"profit":true},{"date":"2023-12-31","value":11.4,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Income | (913.15K) | (1.11M) | (574.37K) | (631.32K) | (5.54M) | [{"date":"2020-12-31","value":-91314700,"profit":false},{"date":"2021-12-31","value":-110906900,"profit":false},{"date":"2022-12-31","value":-57437400,"profit":false},{"date":"2023-12-31","value":-63132200,"profit":false},{"date":"2024-12-31","value":-554023600,"profit":false}] |
| Total Non-Operating Income/Expense | - | 44.00 | (48.59K) | (152.35K) | (966.74K) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-110420.45,"profit":false},{"date":"2023-12-31","value":-346250,"profit":false},{"date":"2024-12-31","value":-2197134.09,"profit":false}] |
| Pre-Tax Income | (913.00) | (1.11M) | (598.59K) | (707.46K) | (6.15M) | [{"date":"2020-12-31","value":-91300,"profit":false},{"date":"2021-12-31","value":-110902500,"profit":false},{"date":"2022-12-31","value":-59859300,"profit":false},{"date":"2023-12-31","value":-70745800,"profit":false},{"date":"2024-12-31","value":-615037200,"profit":false}] |
| Income Taxes | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | - | (1.11M) | (598.59K) | (707.46K) | (6.15M) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-110902500,"profit":false},{"date":"2022-12-31","value":-59859300,"profit":false},{"date":"2023-12-31","value":-70745800,"profit":false},{"date":"2024-12-31","value":-615037200,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (913.00) | (1.11M) | (598.59K) | (707.46K) | (6.15M) | [{"date":"2020-12-31","value":-91300,"profit":false},{"date":"2021-12-31","value":-110902500,"profit":false},{"date":"2022-12-31","value":-59859300,"profit":false},{"date":"2023-12-31","value":-70745800,"profit":false},{"date":"2024-12-31","value":-615037200,"profit":false}] |
| EPS (Diluted) | - | - | 0.09 | 0.08 | (0.31) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.09,"profit":true},{"date":"2024-12-31","value":-352.27,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| KLTO | |
|---|---|
| Cash Ratio | 79.10 |
| Current Ratio | 83.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| KLTO | |
|---|---|
| ROA (LTM) | -71.63% |
| ROE (LTM) | -198.28% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| KLTO | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.01 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.99 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| KLTO | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 1.60 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Klotho Neurosciences, Inc. (KLTO) share price today is $0.236
Yes, Indians can buy shares of Klotho Neurosciences, Inc. (KLTO) on Vested. To buy
Yes, you can purchase fractional shares of Klotho Neurosciences, Inc. (KLTO) via the Vested app. You can start investing in Klotho Neurosciences, Inc. (KLTO) with a minimum investment of $1.
You can invest in shares of Klotho Neurosciences, Inc. (KLTO) via Vested in three simple steps:
The 52-week high price of Klotho Neurosciences, Inc. (KLTO) is $2.45. The 52-week low price of Klotho Neurosciences, Inc. (KLTO) is $0.11.
The price-to-earnings (P/E) ratio of Klotho Neurosciences, Inc. (KLTO) is
The price-to-book (P/B) ratio of Klotho Neurosciences, Inc. (KLTO) is 1.60
The dividend yield of Klotho Neurosciences, Inc. (KLTO) is 0.00%
The market capitalization of Klotho Neurosciences, Inc. (KLTO) is $15.67M
The stock symbol (or ticker) of Klotho Neurosciences, Inc. is KLTO
Consider the share price of Klotho Neurosciences, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Klotho Neurosciences, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Klotho Neurosciences, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Klotho Neurosciences, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Klotho Neurosciences, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Klotho Neurosciences, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
